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The present investigation shows that C3 (hemolytic inactive) as well as C3b and C3d bmd Raji, a CR?-positive Burkitt lymphoma-derived cell line. 
Pretreatment of the cells wtth OKB-7 Inhibited the binding of C3, whereas pretreatment with HB-5 inhibited the bindmg of C3b. Furthermore, 
the cells coated either with OKB-7 or HB-5 bound high amounts of C3d. TPA-treated cells showed bmding for C3b and weak binding for C3 and 
C3d. Taken together, the data suggest that RaJi cells may express three binding sites for C3. C3b and C3d which can be differently modulated by 
anti-CR2 MoAbs and TPA. 
C3: C3b: C3d: CR2; Anti-CR2 MoAbs; TPA 
1. INTRODUCTION 
It has been reported that Burkitt lymphoma cell lines 
and certain human cultured tumor cell lines activate 
complement through the alternative pathwy (ACP) [l- 
41. Mold et al. have shown that ACP activation by Raji 
cells occurs on CR2 molecules which also contain the 
C3 fragments acceptor sites [5]. CR2-positive cells bind 
C3 fragments [6-l l] but not native C3. Native C3 con- 
tains an intramolecular reactive thioester bond which 
allows it to attach covalently, following a transacylation 
reaction, to receptive surfaces [12,13]. This thioester 
bond may undergo hydrolysis at a very slow rate, as 
during prolonged storage, or following treatment with 
chaotropes or ammonium [14-l 71, the resulting C3 mol- 
ecules are uncleaved but devoid of hemolytic activity. 
In contrast to native C3, hemolytic inactive C3 was 
found to have markedly enhanced affinity for the C3b 
receptor [IS]. 
We started the present investigation employing Raji 
cells, which in repeated experiments was shown to only 
possess CR2 from the complement receptors (reviewed 
in [19,20]), in order to answer the question whether 
hemolytic-inactive C3 would bind to them. The next 
question we addressed was to elucidate whether the 
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binding sites on Raji cells for C3, C3b and C3d would 
be the same or not. For this purpose we used human C3, 
C3b and C3d preparations, two anti-CR2 MoAbs 
(OKB-7 and HB-5) and TPA. It has been shown that 
OKB-7 and HB-5 recognize different CR2 epitopes [21] 
and that the pretreatment of the cells with anti-CR2 
MoAbs does not inhibit C3-fragments fixation [5,22]. 
On the other hand, TPA is a strong cellular activator 
[23326] which causes CR2 phosphorylation [27,28]. It 
was worth to use these compounds in order to examine 
their role in modulating the binding of C3 preparations 
to Raji cells. 
2. MATERIALS AND METHODS 
2.1. c3 conlponerlts 
Hemolytic active-C3 (C3,,0 118 units/mg protein) was from Sigma 
Chemical Co, St. Louis. MO, USA; C3b, C3c and C3d [29,30] were 
kindly supplied by Dr J. Lambrts, Base1 Institute for Immunology, 
Basel. Switzerland. Active-C3 was stored for ten months at -80°C 
before use (C3). The hemolytic activity of C3 was determmed by a 
standard assay [31]. 
2.2 Iodinatlon of C3 preparations 
C3 and C3 derived fragments were radiolabeled by the iodogen 
method [32]. Briefly, C3 (20 p(g), C3b (6.5 pg). C3c (7 8 pg) and C3d 
(14 fig) were incubated with the same respective amounts of dry 
1.3,4.6-tetrachloro-3a-6a-diphenylglycouryl (Sigma) and 0.1 mCi 
“‘Iodine (“‘I) (NEN, Frankfurt, Germany) for 10 mm at room tem- 
perature. Afterwards, the samples were diluted with 1 ml of phos- 
phate-buffered saline (PBS) and dialyzed against PBS at 4°C for 18 
h. The specific activity was for C3, 2.5 @/mg: for C3b, 7.01 &i/mg; 
for C3c IO pCi/pg; and for C3d. 7.0 flCi/flg. In repeated labehng the 
specific activities of C3-preparations were different. In order to ex- 
plore whether C3 was cleavable by physical treatment, radiolabeled 
C3 was stored for 24 h at -20°C. durmg which time it was thawed and 
frozen twice. 
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2.3. Cells and experunentirl procedure 2.5. SDS-PAGE 
Raji cell were cultured in RPMI-1640 (Flow Lab. Ltd. Irvine. 
Ayrshire. Scotland) supplemented with 10% heat inactivated fetal calf 
serum (FCS) (Flow). 0.1 ml of 1 x 107cells/ml. previously washed with 
cold PBS. were Incubated for 30 mm at 4°C or 37” with anti-CR2 
MoAbs (lOpg/ml) or with TPA (30 ng/ml) (Sigma) The washed cells. 
resuspended in 0 1 ml PBS, were incubated with radiolabeled C3 (IO 
PI), C3b and C3d (5 ~1) at 4°C and 37°C (TPA-treated cells) or 4°C 
(MoAb-coated cells) for 30 mm in a tinal volume of 0.12 ml. After- 
wards, the cells were washed and the radioactivity counted m a y 
counter and dissolved in 50 ~1 of Laemmli’s buffer [33] containing 
2-mercaptoethanol (1 mM), (Sigma) 
SDS-PAGE was carried out with slab gels of 10.5% or a 7.5520% 
gradient of polyacrylamide. For each run, radiolabeled molecular 
weight markers (NEN) or prestamed standard proteins (Bio-Rad. 
Richmond. CA, USA) were included. Before loadmg, the samples 
were sonicated (Sum-Prep) for 10 s and boiled for 3 min. After electro- 
phoresis. the dried gels were exposed for 2 3 days at -80°C to New 
X-Ray film (Fuji Photo film Co Ltd. Japan). 
3. RESULTS 
2.4. Inmlunofluorescence 
3.1. Churacteristm of C3. C3h md C3d preparatioil 
Reactivity of the membrane bound molecules with HB-5 (Beckton 
Dickinson. Mountam View, CA, USA), 0KB7 (Ortho Pharmaceutical 
Corp..Raritan. NJ USA), anti-human C3b-receptor (14 pug/ml) and 
anti-human C3bi-receptor (7 &ml) (Dakopatts. Copenahagen, Den- 
mark) was detected by indirect immunofluorescence using Auorescm 
isothiocyanate (FIT0conjugated rabbit anti-mouse Ig (Cappel, West 
Chester. PA. USA). Reactivity with this reagent alone served as neg- 
ative control. For some experiments direct FITC was performed by 
usmg anti-C3d-FITC (17 pug/ml) (Dakopatts). The samples were ana- 
lyzed in Facscan (Beckton Dickmson) 
Hemolytic active C3 was stored for ten months at 
-80°C. During this period the hemolytic titer (C3,,,) 
declined from 118 U/mg to 5 U/mg. C3 showed the 
typical a and p chains of 115 and 75 kDa, respectively 
(Fig. 1 a). The radiolabeled preparation following freez- 
ing and thawing showed its intact chains and two not 
well defined fragments (Fig. 1 b). C3b showed the a’ and 
p chains of 105 kDa and of 75 kDa, respectively (Fig. 
2, lane a). The C3d preparation, consisted of a 35 kDa 
band (Fig. 2, lane c). C3c was used as internal marker 
(Fig. 2, lane b). The binding of C3 to Raji cells was 
dose-dependent as detected by cytofluorimetric analysis 
and saturation was achieved at a concentration of 




3.2. Detection of CRI. CR7 und CR3 on Ruji cells 
Cytofluorimetry showed that Raji cells were CR2- 
positive (99%). but not CRl- (0.8%) and CR3-positive 
(6%) (data not shown). 
3.3. Binding of C3. C3b and C3d to Ruji cells is tenlper- 
ature-seruitiw 
The radioiodinated C3 preparations were incubated 
with Raji cells for 30 min at 4°C or at 37°C. C3. C3b 
and C3d bound to the cells at 4°C (Fig. 4, lanes a,c.d) 
and in larger amounts at 37°C (Fig. 4, lanes b.d.f). The 
amount of the C3 preparations bound to Raji cells at 
37°C is shown, in terms of cpm, in Fig. 5A. The temper- 
ature sensitive binding of C3 was also detectable by 
cytofluorimetry as shown in Fig. 6. 
a 
Fig. 1. SDS-PAGE autoradiography of C3. [“51]-C3 (lane a), and 
[“51]-C3 frozen and thawed twice (lane b) were run under reducmg 
conditions on a 7.5520% SDS-PAGE gradient. 
a b c 
Fig. 2. SDS-PAGE autoradiography of C3b, C3c and C3d Radiola- 
beled C3b (lane a), C3c (lane b) and C3d (lane c) were run under 
reducing conditions on a 10.5% SDS-PAGE (mini gel). 
320 
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Fig. 3. Dose-dependent binding of C3 to Raji cells. 1 x 10h Raji cells 
were incubated with PBS (A) or with 0.1 pug (B). 0.4pg (C), 1 pg (D), 
2 pg (E) and 5 pg (F) of C3 for 30 min at 4°C. Afterwards. the washed 
cells were Incubated with ant]-C3d-FITC for 30 mm at 4°C. washed 
and analyzed in Facscan. The mean value of the fluorescent peaks 
plotted versus the fig of C3 added to the mcubatton system IS also 
reported. 
3.4. Anti-CR2 MoAbs, OKB-7 and HB-5, modulate the 
binding sites on Raji cells for C3, C3b and C3d 
Treatment of Raji cells with 0KB7 and HB5 was 
performed both at 4°C and 37°C. whereas the relative 
binding with the radiolabeled preparations was done at 
4°C. This experimental approach allowed us to evaluate 
eventual differences of binding of the C3 preparations. 
The binding of C3 and C3d to 4”C-OKB7-coated 
cells was weak (Fig. 7, lanes a,c). The binding of C3 to 
37”C-OKB7-coated cells was undetectable, whereas 
that for C3d was high (Fig. 7, lanes b,d). The binding 
of C3b to OKB7-coated Raji cells was low (data not 
shown). 
The results with HBS-coated Raji cells were partly 
similar (Fig. 7, lanes e-j). 4°C HBS-coated cells showed 
binding to C3. C3b and C3d (lanes e,g,i). 37”C-HBS- 
coated cells bound C3 (lane f). to a high extent C3d (lane 
j), whereas C3b was undetectable (lane h). 
The amount of the C3 preparations bound to 37°C 
anti-CR2 MoAb coated-Raji cells is shown, in terms of 
cpm, in Fig. 5B,C. 
The results indicate that C3 and C3b may bind differ- 
ent binding sites and that treatment of the cells with 
anti-CR2 MoAbs increased the binding of monomeric 
C3d. 
3.5. TPA modulates the binding sites on Ruji cells for 
C3, C3b and C3d 
37°C TPA-treated-Raji cells bound C3 and C3d to a 
low extent (Fig. 8, lanes b,f) and showed high binding 
capacity for C3b (Fig. 8, lane d). The amount of the C3 
preparations bound to TPA-treated Raji cells is shown, 
in terms of cpm, in Fig. 5D. The results demonstrate 
that C3 and C3d binding sites are different from those 
of C3b. 
Fig. 5 clearly shows that the binding sites for the C3 
preparations may be differently expressed following the 
interaction of the cells with anti-CR2 MoAbs and TPA. 
3.6. Binding of C3 to CR2 
Raji cells incubated with C3 showed an anti-C3d- 
FITC peak (Fig. 9a) that was shifted toward the left 
when OKB7-coated cells were incubated with the same 
amount of C3 (Fig. SC) indicating that OKB7 inhibited 
the binding of C3 to CR2. HB5 did not affect the bind- 
ing of C3 (Fig. 9d). 
4. DISCUSSION 
In the present study we have investigated the capacity 
of Raji cells to bind C3 and C3-derived fragments. 







Fig. 4. SDS-PAGE autoradiography of C3, C3b and C3d bound to 
Raji cells. Raji cells were Incubated wtth [“‘I]-C3 (lanes a.b); [“51]-C3b 
(lanes c.d) and [“51]-C3d (lanes e.0 for 30 min at 4°C (lanes a,c.e) or 
at 37°C (lanes b.d,f). The washed cells were dissolved in Laemmli’s 
buffer and run under reducmg condttrons on a 7 5-20% SDS-PAGE 
gradient 
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Ftg. 5. Histograms of C3. C3b and C3d cpm bound to Rajl cells. Panel 
A. Rajt were mcubated for 30 mm with C?. C3b and C3d at 37’C 
Panel B: Rajt were Incubated for 30 mm with ORB-7 at 37°C. After- 
wards. the washed cells were mcubated wtth the radtolabeled prepara- 
ttonb for 30 mm at 4°C. Panel C, R~JI were Incubated for 30 mmutes 
wtth HB-5 at 37°C. Thereafter, the washed cells were mcubated urth 
the radtolabeled preparattons for 30 mtn at 4°C. Panel D, R~JI here 
Incubated for 30 mm wtth TPA at 37’C Afterwards. the hashed cells 
were incubated wtth the radtolabeled preparatrons for 3tl mm at 37°C. 
Bound radtoacttvity was counted m a y-counter. The results derive 
from one single expertment, but they arc representatrve of three exper- 
iments performed wrth dtfferent radrolabelcd preparattons (Table I). 
The C3 used was hemolytically inactive, due to the 
long storage of original active C3 at low temperature 
[14]. Raji cells bound this form of C3 in a dose-depend- 
ent fashion in the range of 10~‘--10~8 M and the molec- 
ular size of cx and /? chains of the reacting molecule did 
not change. Also physical treatment did not cause cleav- 
age of this C3 preparation. These results confirm that 
hemolytic inactive C3 does not undergo autolytic cleav- 
age [ 171 and that it can bind cell surfaces [18]. However. 
in the case of CRl-negative Raji cells the binding site 
for C3 has to be offered by another membrane protein. 
It has been shown that the binding of C3b to CR2- 
positive cells is temperature-sensitive [ 10) and this char- 
acteristic can also be applied to C3 and C3d as demon- 
strated above. These and other unpublished data sup- 
port the hypotesis that the temperature-sensitive bind- 
ing of CR2 ligands to Raji cells may be due to a disclos- 
ing process of hidden or new binding sites on the cell 
surface similar to that described on mucins [34]. 
Multiple C3 binding sites for CR2 have been pre- 
dicted [35]. We used the radiolabeled C3 preparations 
in the concentration range of 2210 nM to reduce the 
possibility of cross-binding of each C3 preparation to 
different and multiple binding sites. Indeed, the binding 
of C3 fragments to CR2-positive cells is rather complex, 
depending on acceptor and receptor binding sites [5-l 1] 
and on the fact that CR2 is the C3d receptor and thus 
potentially able to bind any molecule bearing and ex- 
posing C3d. The aspect of multiple binding sites was 
then approached by treating the cells with anti-CR2 
MoAbs or with TPA and thereafter with the radiola- 
beled C3 preparations at temperatures and concentra- 
tions that allowed to evaluate their modulation. TPA 
and anti-CR2 MoAbs. in fact, induce activation and 
different fate of CR’-positive cells [26-28.361, according 
to specific signaling of different triggers 1371. 
OKB-7 determined a decrease of the binding of C3, 
while HB-5 was inhibitory for C3b. These two MoAbs 
recognize different SCRs on CR2 [21] and some epi- 
topes recognized by OKB7 [38] should also be recog- 
nized by C3 since OKB7 and not HB5 inhibited the 
binding of C3. These results. derived from autoradi- 
ographic analysis. were fully confirmed by cytofluori- 
metric studies. Therefore, it is evident that C3 binds 
CR2 on Raji cells. 
The binding of C3d molecules to anti-CR2 MoAb- 
coated cells was the result of an active cellular metabo- 
lism since this result was obtained following incubation 





F I uclrescence 
Fig 6 Temperature sensrttve bindmg of C3 to R~JI cells. Rajt were 
incubated wtth PBS (a) and I pg of C3 tb.c) for 30 min at 4°C (a,b) 
or 37°C (c). The washed cells uere Incubated with anti-C3d-FITC for 
30 min at 4°C. washed and analyzed in Facscan. The percent of 
postttve cell (top value) and the fluorescent peak mode (bottom value) 
are also reported m each panel. 
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Fig. 7. SDS-PAGE autoradiography of C3, C3b and C3d bound to 
anti-CR2 MoAb coated-Raji cells. RaJi cells were incubated with 
OKB7 (lanes aad) or HB5 (lanes e-j) for 30 nun at 4°C (lanes a.c,e.g.i) 
or at 37°C (lanes b,d,f,hJ). The cells were washed and then incubated 
with [“‘I]-C3 (lanes a.b,e,f). [“51]-C3b (lanes g,h) and [“‘I]-C3d (lanes 
c.d.1.j) for 30 mm at 4°C. The washed pellets were dissolved m 
Laemmh’s buffer and run under reducing conditions on a 7.5520% 
SDS-PAGE gradient. 
Table I 
RaJi cells were incubated with PBS. 0KB7. HB5 and TPA for 30 
minutes at 37°C 
cpm bound 
Treatment c3 C3b C3d 
(a) PBS treated-Raji 
(b) OKB7 coated-Ran 
(c) HB5 coated-Ran 
(d) TPA treated RaJi 
* 25.907 39.002 42.531 
** 18.940 20.811 37.940 
*** 21.354 18 673 26.539 
* 6 448 18.340 77 718 
** 9.340 19.870 53.739 
*** 7.374 10.352 55.392 
* 18.637 9.827 80.000 
** 26.352 6.025 49.818 
*** 25.396 13.438 33.000 
* 11.588 48.997 9.715 
** 8.320 16.400 20.341 
*** 2.022 33 100 5 409 
Washed cells were Incubated with radiolabeled C3, C3b and C3d at 
37°C (a,d) or at 4°C (b.c) for 30 mm. Afterwards the cells were washed 
and the radioactivity counted m a y counter. Single values of three 
different experiments whose specific activities were: *C3, 2.5 &i/pg. 
C3b, 7.01 pCi/pg, C3d, 7.0 @i/pg; **C3 1.9 pCi/pg. C3b 4.8 ,&Zil~g, 
C3d 6.7 ,uCi/pg. ***C3 2 2 ,uCil,ug. C3b 8.2 ,uCil,ug. C3d, 7.6 ,uCilpg. 
in contrast with data showing a competitive or common 
binding between OKB-7 and C3dg on CR2 [21,39]. 
Most likely, this is due to the fact that our data derive 
from experiments in which CR2-positive cells and not 
purified CR2 have been used. However, the C3d bind- 
ing sites present on anti-CR2 MoAb-coated cells would 
be related to those responsible for the fixation of C3- 
related fragments on a cell surface which is not inhibited 
by anti-CR2 MoAbs [5.22]. 
In this study we also investigated the differences of 
the binding of C3 preparations following cell activation 
by TPA which has been shown to be inhibited by mon- 
omeric C3dg [26]. Our results demostrate that TPA- 
treated cells bound C3b whereas the binding of C3 and 
C3d was strongly inhibited if compared to the control, 
thus demonstrating that C3b may bind different binding 
sites from those recognized by C3 and C3d. 
Taken together these data indicate that Raji cells may 
express on their surface three binding sites, respectively 
for C3 (hemolytically inactive), C3b and C3d, which can 
be modulated by anti-CR2 MoAbs or TPA. 
A final aspect to be taken into account is that under 
our experimental conditions the C3 preparations were 
never further cleaved. thus indicating that they may 
exist as stable cellular ligands. 
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Fig. 8. SDS-PAGE autoradiography of C3, C3b and C3d bound to 
TPA treated-Raji cells. Raji cells were incubated with PBS (lanes a.c.e) 
or TPA (30 ng/ml) (lanes b,d.f)) for 30 min at 37°C. Afterwards the 
cells were washed and incubated with [“‘I]-C3 (lanes a,b). [“‘I]-C3b 
(lanes c.d), and [“51]-C3d (lanes e.f) for 30 min at 37°C. The washed 
pellets were dissolved m Laemmli’s buffer and run under reducing 
conditions on a 7.5520% SDS-PAGE gradient. 
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F I uorescence 
Fig. 9. Cytofluorimetry of C3 bound to R~JI cells. 1 x 10” R~JI were 
incubated wtth PBS (a). 1 pg of C3 (b). 1 pg of 0KB7 (c). I pug of HB5 
(d) for 30 mm at 4°C The washed cells were incubated with PBS (a.b) 
or 1 pg of C3 (c,d) for 30 min at 4°C. Afterwards the washed cells were 
incubated with antt-C3d-FITC for 30 mm at 4°C. washed and ana- 
lyzed in Facscan. The percent of positive cell (top value) and the mode 
of fluorescent (bottom value) are also reported m each panel. 
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